Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) will be issuing its quarterly earnings data after the market closes on Monday, July 31st. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Threshold Pharmaceuticals (NASDAQ:THLD) last issued its earnings results on Monday, May 15th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. On average, analysts expect Threshold Pharmaceuticals to post $-0.29 EPS for the current fiscal year and $-0.39 EPS for the next fiscal year.

Threshold Pharmaceuticals, Inc. (THLD) opened at 0.494 on Monday. The stock’s market capitalization is $35.37 million. The firm has a 50-day moving average of $0.44 and a 200 day moving average of $0.52. Threshold Pharmaceuticals, Inc. has a one year low of $0.35 and a one year high of $1.48.

COPYRIGHT VIOLATION NOTICE: “Threshold Pharmaceuticals, Inc. (THLD) to Release Quarterly Earnings on Monday” was posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at

Separately, ValuEngine raised shares of Threshold Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 6th.

In other news, Director Jeffrey W. Bird purchased 510,703 shares of the firm’s stock in a transaction on Thursday, June 1st. The stock was acquired at an average cost of $0.57 per share, with a total value of $291,100.71. Following the completion of the transaction, the director now owns 919 shares in the company, valued at approximately $523.83. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.97% of the company’s stock.

Threshold Pharmaceuticals Company Profile

Threshold Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib.

Earnings History for Threshold Pharmaceuticals (NASDAQ:THLD)

Receive News & Ratings for Threshold Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Threshold Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.